Compounds > 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin d3
Page last updated: 2024-08-01 11:32:13
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin d3
Description
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: long lasting analog of calcitriol; RN given refers to (1alpha,3beta,5Z,7E)-isomer [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5282190 |
| CHEMBL ID | 2106158 |
| SCHEMBL ID | 3754 |
| SCHEMBL ID | 15263837 |
| MeSH ID | M0120543 |
Synonyms (49)
| Synonym |
|---|
| 26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxyvitamin d3 / 26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxycholecalciferol |
| (5z,7e)-(1s,3r)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol |
| LMST03020089 |
| 9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, 26,26,26,27,27,27-hexafluoro-, (1-alpha,3-beta,5z,7e)- |
| calcitriol hexafluoride |
| ro 23-4194 |
| hornel, fulstan |
| 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin d3 |
| st 630 |
| falecalcitriol [inn] |
| (+)-(5z,7e)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol |
| HY-32342 |
| f6-1alpha,25(oh)2d3 |
| gtpl2781 |
| hexafluorocalcitriol |
| fulstan |
| horner |
| ro-23-4194 |
| falecalcitriol |
| dsc-103 |
| st-630 |
| flocalcitriol |
| falecalcitriol (jan/inn) |
| 83805-11-2 |
| hornel (tn) |
| D01662 |
| (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
| unii-g70a8514t8 |
| g70a8514t8 , |
| falecalcitoriol |
| hornel |
| CHEMBL2106158 |
| CS-0801 |
| falecalcitriol [mart.] |
| falecalcitoriol [jan] |
| falecalcitriol [jan] |
| falecalcitriol [who-dd] |
| (+)-(5z,7e)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1.alpha.,3.beta.,25-triol |
| SCHEMBL3754 |
| SCHEMBL15263837 |
| (1r,3s,z)-5-(2-((1r,3as,7ar,e)-7a-methyl-1-((r)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl)octahydro-4h-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol |
| AKOS025312291 |
| f6vd3 |
| Q5431843 |
| falecalcitol |
| (1s,3r,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol |
| F84840 |
| MS-29711 |
| DTXSID601027560 |
Research
Studies (42)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 5 (11.90) | 18.7374 |
| 1990's | 19 (45.24) | 18.2507 |
| 2000's | 15 (35.71) | 29.6817 |
| 2010's | 3 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 5 (11.11%) | 5.53% |
| Reviews | 5 (11.11%) | 6.00% |
| Case Studies | 2 (4.44%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 33 (73.33%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Acute Myelogenous Leukemia | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Acute Promyelocytic Leukemia | 0 | | 1992 | 1995 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Adult Rickets | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Age-Related Osteoporosis | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Anemia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bone Loss, Osteoclastic | 0 | | 1990 | 1999 | 30.2 | low | 0 | 0 | 4 | 0 | 0 | 0 |
| Bright Disease | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cell Transformation, Viral | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Kidney Failure | 0 | | 2002 | 2016 | 16.9 | low | 2 | 0 | 0 | 6 | 1 | 0 |
| Complications of Diabetes Mellitus | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Deficiency, Vitamin D | 0 | | 1989 | 1998 | 30.0 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| Glomerulonephritis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granulocytic Leukemia | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Hyperparathyroidism | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperparathyroidism, Secondary | 0 | | 1998 | 2016 | 17.7 | medium | 3 | 0 | 1 | 7 | 1 | 0 |
| Hypocalcemia | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypoparathyroidism | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Idiopathic Hypoparathyroidism | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kidney Failure, Chronic | 0 | | 2002 | 2016 | 16.9 | low | 2 | 0 | 0 | 6 | 1 | 0 |
| Leucocythaemia | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Leukemia | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Leukemia, Myeloid | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Leukemia, Myeloid, Acute | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Leukemia, Promyelocytic, Acute | 0 | | 1992 | 1995 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Osteomalacia | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Osteoporosis | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Palmoplantaris Pustulosis | 0 | | 2000 | 2001 | 23.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Psoriasis | 0 | | 2000 | 2001 | 23.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Rachitis | 0 | | 1984 | 2002 | 31.0 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| Secondary Hyperparathyroidism | 0 | | 1998 | 2016 | 17.7 | medium | 3 | 0 | 1 | 7 | 1 | 0 |
| Uremia | 0 | | 1991 | 2009 | 24.0 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Vitamin D Deficiency | 0 | | 1989 | 1998 | 30.0 | low | 0 | 1 | 2 | 0 | 0 | 0 |
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.PloS one, , Volume: 11, Issue:10, 2016
Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.Clinical nephrology, , Volume: 71, Issue:6, 2009
Vitamin D receptor activators.The International journal of artificial organs, , Volume: 32, Issue:2, 2009
Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.Clinical nephrology, , Volume: 69, Issue:5, 2008
[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients].Clinical calcium, , Volume: 16, Issue:5, 2006
[Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism].Clinical calcium, , Volume: 15, Issue:1, 2005
[The trend in the development of the active vitamin D3 and its analogues].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 5, 2004
[Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 120, Issue:6, 2002
Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 32, Issue:2, 1998
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.PloS one, , Volume: 11, Issue:10, 2016
Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.Clinical nephrology, , Volume: 71, Issue:6, 2009
Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.Clinical nephrology, , Volume: 69, Issue:5, 2008
[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients].Clinical calcium, , Volume: 16, Issue:5, 2006
[Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism].Clinical calcium, , Volume: 15, Issue:1, 2005
[The trend in the development of the active vitamin D3 and its analogues].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 5, 2004
[Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 120, Issue:6, 2002
Effect of growth hormone (GH) therapy on parathyroid hormone metabolism in a girl with GH deficient short stature and chronic renal failure.Journal of pediatric endocrinology & metabolism : JPEM, , Volume: 9, Issue:5
Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study.The British journal of dermatology, , Volume: 144, Issue:3, 2001
Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1,25-dihydroxyvitamin D3.The British journal of dermatology, , Volume: 143, Issue:1, 2000
Vitamin D receptor activators.The International journal of artificial organs, , Volume: 32, Issue:2, 2009
Clinical trial of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in uremic patients on hemodialysis: preliminary report.Contributions to nephrology, , Volume: 90, 1991
Effect of 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3 on the expression of vitamin-D-responsive genes in vitamin-D-deficient mice.Pharmacology, , Volume: 57, Issue:6, 1998
Preparation and biological activity of 24-epi-26,26,26,27,27,27-hexafluoro- 1 alpha,25-dihydroxyvitamin D2.Chemical & pharmaceutical bulletin, , Volume: 43, Issue:11, 1995
Biological activity of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in the chick.Acta endocrinologica, , Volume: 121, Issue:4, 1989
Biological activities of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 on human promyelocytic leukemic HL-60 cells: effects of fetal bovine serum and of incubation time.Mineral and electrolyte metabolism, , Volume: 21, Issue:1-3, 1995
Effects of vitamin D-binding proteins on HL-60 cell differentiation induced by 26,26,26,27,27,27-hexafluoro-1 alpha,25-dihydroxyvitamin D.The Journal of steroid biochemistry and molecular biology, , Volume: 41, Issue:1, 1992
Effect of hexafluoro-1,25-dihydroxyvitamin D3 and sodium butyrate combination on differentiation and proliferation of HL-60 leukemia cells.Anticancer research, , Volume: 12, Issue:6B
Comparison of 26,27-hexafluoro-1 alpha,25-dihydroxyvitamin D3 and 1 alpha,25-dihydroxyvitamin D3 on the resorption of bone explants ex vivo.Journal of nutritional science and vitaminology, , Volume: 45, Issue:3, 1999
Differences in metabolism between 26,26,26,27,27,27-hexafluoro-1 alpha, 25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in cultured neonatal mouse calvaria.Research communications in molecular pathology and pharmacology, , Volume: 86, Issue:2, 1994
Effects on cultured neonatal mouse calvaria of 1 alpha,25-dihydroxyvitamin D3, 26,26,26,27,27,27-hexafluoro-1 alpha,25-dihydroxyvitamin D3 and 26,26,26,27,27,27-hexafluoro-1 alpha,23S,25-trihydroxyvitamin D3.Bone and mineral, , Volume: 18, Issue:1, 1992
26,27-Hexafluoro-1,25-dihydroxyvitamin D3 (F6-1,25(OH)2D3) prevents osteoporosis induced by immobilization combined with ovariectomy in the rat.Bone and mineral, , Volume: 9, Issue:2, 1990
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.PloS one, , Volume: 11, Issue:10, 2016
Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.Clinical nephrology, , Volume: 71, Issue:6, 2009
Vitamin D receptor activators.The International journal of artificial organs, , Volume: 32, Issue:2, 2009
Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.Clinical nephrology, , Volume: 69, Issue:5, 2008
[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients].Clinical calcium, , Volume: 16, Issue:5, 2006
[Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism].Clinical calcium, , Volume: 15, Issue:1, 2005
[The trend in the development of the active vitamin D3 and its analogues].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 5, 2004
[Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 120, Issue:6, 2002
Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 32, Issue:2, 1998
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.PloS one, , Volume: 11, Issue:10, 2016
Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.Clinical nephrology, , Volume: 71, Issue:6, 2009
Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.Clinical nephrology, , Volume: 69, Issue:5, 2008
[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients].Clinical calcium, , Volume: 16, Issue:5, 2006
[Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism].Clinical calcium, , Volume: 15, Issue:1, 2005
[The trend in the development of the active vitamin D3 and its analogues].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 5, 2004
[Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 120, Issue:6, 2002
Effect of growth hormone (GH) therapy on parathyroid hormone metabolism in a girl with GH deficient short stature and chronic renal failure.Journal of pediatric endocrinology & metabolism : JPEM, , Volume: 9, Issue:5
Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study.The British journal of dermatology, , Volume: 144, Issue:3, 2001
Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1,25-dihydroxyvitamin D3.The British journal of dermatology, , Volume: 143, Issue:1, 2000
[Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].Nihon yakurigaku zasshi. Folia pharmacologica Japonica, , Volume: 120, Issue:6, 2002
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D3.Archives of biochemistry and biophysics, , Feb-15, Volume: 229, Issue:1, 1984
Effect of 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3 on the expression of vitamin-D-responsive genes in vitamin-D-deficient mice.Pharmacology, , Volume: 57, Issue:6, 1998
Preparation and biological activity of 24-epi-26,26,26,27,27,27-hexafluoro- 1 alpha,25-dihydroxyvitamin D2.Chemical & pharmaceutical bulletin, , Volume: 43, Issue:11, 1995
Biological activity of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in the chick.Acta endocrinologica, , Volume: 121, Issue:4, 1989
Biological activities of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 on human promyelocytic leukemic HL-60 cells: effects of fetal bovine serum and of incubation time.Mineral and electrolyte metabolism, , Volume: 21, Issue:1-3, 1995
Effects of vitamin D-binding proteins on HL-60 cell differentiation induced by 26,26,26,27,27,27-hexafluoro-1 alpha,25-dihydroxyvitamin D.The Journal of steroid biochemistry and molecular biology, , Volume: 41, Issue:1, 1992
Effect of hexafluoro-1,25-dihydroxyvitamin D3 and sodium butyrate combination on differentiation and proliferation of HL-60 leukemia cells.Anticancer research, , Volume: 12, Issue:6B
Dosage (5)
| Article | Year |
|---|
Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 31, Issue:8 | 2003 |
In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum lev
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 29, Issue:6 | 1999 |
Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 32, Issue:2 | 1998 |
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D3.
Archives of biochemistry and biophysics, , Feb-15, Volume: 229, Issue:1 | 1984 |
Effect of hexafluoro-1,25-dihydroxyvitamin D3 and sodium butyrate combination on differentiation and proliferation of HL-60 leukemia cells.
Anticancer research, , Volume: 12, Issue:6B | |